RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration

Authorized Users Only
2020
Authors
Mojsilović, Sonja
Tošić, Milica
Mojsilović, Slavko
Živanović, Marija
Bjelica, Sunčica
Srdić-Rajić, Tatjana
Santibanez, Juan
Article (Published version)
Metadata
Show full item record
Abstract
Purpose: Transforming growth factor-beta (TGF-beta) induces alternative macrophage activation that favors tumor progression and immunosuppression. Meanwhile, paclitaxel (PTx) induces macrophage (M phi) polarization towards antitumor phenotype. TGF-beta also increases tumor stroma macrophage recruitment by mechanisms that include cell motility enhancement and extracellular matrix degradation. In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta. Methods: We used mouse macrophage RAW 264.7 cells treated with PTx and TGF-beta combinations. Proliferation was analyzed by MTT and cell cycle assays. Immunofluorescence was performed to determine tubulin cytoskeleton and Smad3 nuclear localization. Western blot and transcriptional luciferase reporters were used to measure signal transduction activation. Migration was determined by wound healing assay. uPA activity was determined by zymograph...y assay. Results: PTx decreased RAW 264.7 cell proliferation by inducing G2/M cell cycle arrest and profoundly modified the tubulin cytoskeleton. Also, PTx inhibited TGF-beta-induced Smad3 activation. Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta. Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition. Conclusions: PTx inhibits TGF-beta induction of mouse M phi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance MT anticancer action within tumors.

Keywords:
macrophages / migration / paclitaxel / proliferation / transforming growth factor-beta / urokinase-type plasminogen activator
Source:
Journal of BUON, 2020, 25, 2, 1257-1265
Publisher:
  • Balkan Union of Oncology (B.U.ON.)
Funding / projects:
  • The pathogenetic mechanism in hematological malignancies (RS-175053)
  • Pharmacodynamic and pharmacogenomic research of new drugs in the treatment of solid tumors (RS-41026)
  • Regenerative and modulatory potential of adult stem cells (RS-175062)

ISSN: 1107-0625

PubMed: 32521934

WoS: 000549860600007

[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_rimi_1067
URI
http://rimi.imi.bg.ac.rs/handle/123456789/1067
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Mojsilović, Sonja
AU  - Tošić, Milica
AU  - Mojsilović, Slavko
AU  - Živanović, Marija
AU  - Bjelica, Sunčica
AU  - Srdić-Rajić, Tatjana
AU  - Santibanez, Juan
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1067
AB  - Purpose: Transforming growth factor-beta (TGF-beta) induces alternative macrophage activation that favors tumor progression and immunosuppression. Meanwhile, paclitaxel (PTx) induces macrophage (M phi) polarization towards antitumor phenotype. TGF-beta also increases tumor stroma macrophage recruitment by mechanisms that include cell motility enhancement and extracellular matrix degradation. In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta. Methods: We used mouse macrophage RAW 264.7 cells treated with PTx and TGF-beta combinations. Proliferation was analyzed by MTT and cell cycle assays. Immunofluorescence was performed to determine tubulin cytoskeleton and Smad3 nuclear localization. Western blot and transcriptional luciferase reporters were used to measure signal transduction activation. Migration was determined by wound healing assay. uPA activity was determined by zymography assay. Results: PTx decreased RAW 264.7 cell proliferation by inducing G2/M cell cycle arrest and profoundly modified the tubulin cytoskeleton. Also, PTx inhibited TGF-beta-induced Smad3 activation. Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta. Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition. Conclusions: PTx inhibits TGF-beta induction of mouse M phi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance MT anticancer action within tumors.
PB  - Balkan Union of Oncology (B.U.ON.)
T2  - Journal of BUON
T1  - Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration
EP  - 1265
IS  - 2
SP  - 1257
VL  - 25
UR  - https://hdl.handle.net/21.15107/rcub_rimi_1067
ER  - 
@article{
author = "Mojsilović, Sonja and Tošić, Milica and Mojsilović, Slavko and Živanović, Marija and Bjelica, Sunčica and Srdić-Rajić, Tatjana and Santibanez, Juan",
year = "2020",
abstract = "Purpose: Transforming growth factor-beta (TGF-beta) induces alternative macrophage activation that favors tumor progression and immunosuppression. Meanwhile, paclitaxel (PTx) induces macrophage (M phi) polarization towards antitumor phenotype. TGF-beta also increases tumor stroma macrophage recruitment by mechanisms that include cell motility enhancement and extracellular matrix degradation. In this study, we aimed to determine whether PTx regulates macrophage migration and urokinase-type plasminogen activator (uPA) expression induced by TGF-beta. Methods: We used mouse macrophage RAW 264.7 cells treated with PTx and TGF-beta combinations. Proliferation was analyzed by MTT and cell cycle assays. Immunofluorescence was performed to determine tubulin cytoskeleton and Smad3 nuclear localization. Western blot and transcriptional luciferase reporters were used to measure signal transduction activation. Migration was determined by wound healing assay. uPA activity was determined by zymography assay. Results: PTx decreased RAW 264.7 cell proliferation by inducing G2/M cell cycle arrest and profoundly modified the tubulin cytoskeleton. Also, PTx inhibited TGF-beta-induced Smad3 activation. Furthermore, PTx decreased cell migration and uPA expression stimulated by TGF-beta. Remarkably, p38 MAPK mediated PTx inhibition of uPA activity induced by TGF-beta but it was not implicated on cell migration inhibition. Conclusions: PTx inhibits TGF-beta induction of mouse M phi migration and uPA expression, suggesting that PTx, as TGF-beta targeting therapy, may enhance MT anticancer action within tumors.",
publisher = "Balkan Union of Oncology (B.U.ON.)",
journal = "Journal of BUON",
title = "Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration",
pages = "1265-1257",
number = "2",
volume = "25",
url = "https://hdl.handle.net/21.15107/rcub_rimi_1067"
}
Mojsilović, S., Tošić, M., Mojsilović, S., Živanović, M., Bjelica, S., Srdić-Rajić, T.,& Santibanez, J.. (2020). Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration. in Journal of BUON
Balkan Union of Oncology (B.U.ON.)., 25(2), 1257-1265.
https://hdl.handle.net/21.15107/rcub_rimi_1067
Mojsilović S, Tošić M, Mojsilović S, Živanović M, Bjelica S, Srdić-Rajić T, Santibanez J. Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration. in Journal of BUON. 2020;25(2):1257-1265.
https://hdl.handle.net/21.15107/rcub_rimi_1067 .
Mojsilović, Sonja, Tošić, Milica, Mojsilović, Slavko, Živanović, Marija, Bjelica, Sunčica, Srdić-Rajić, Tatjana, Santibanez, Juan, "Paclitaxel inhibits transforming growth factor-beta-increased urokinase-type plasminogen activator expression through p38 MAPK and RAW 264.7 macrophage migration" in Journal of BUON, 25, no. 2 (2020):1257-1265,
https://hdl.handle.net/21.15107/rcub_rimi_1067 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB